583 related articles for article (PubMed ID: 17188172)
41. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Krampitz GW; Norton JA
Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
[TBL] [Abstract][Full Text] [Related]
42. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.
Jasim S; Ying AK; Waguespack SG; Rich TA; Grubbs EG; Jimenez C; Hu MI; Cote G; Habra MA
Thyroid; 2011 Feb; 21(2):189-92. PubMed ID: 21186952
[TBL] [Abstract][Full Text] [Related]
43. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
[TBL] [Abstract][Full Text] [Related]
44. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
Chang CF; Yang WS; Su YN; Wu IL; Chang TC
J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
[TBL] [Abstract][Full Text] [Related]
45. [Prophylactic thyroidectomy in medullary thyroid cancer].
Peix JL; Lifante JC; Borson CF; Giraud S
Bull Acad Natl Med; 2012 Oct; 196(7):1247-58; discussion 1258-60. PubMed ID: 23815012
[TBL] [Abstract][Full Text] [Related]
46. Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective.
Brauckhoff M; Machens A; Lorenz K; Bjøro T; Varhaug JE; Dralle H
Ann Surg; 2014 Apr; 259(4):800-6. PubMed ID: 23979292
[TBL] [Abstract][Full Text] [Related]
47. [Clinical and genetic profile of patients with medullary thyroid cancer treated in the Cancer Centre--Institute of Oncology in Warsaw].
Czetwertyńska M; Kozłowicz-Gudzińska I; Stachlewska-Nasfeter E; Sromek M; Skasko E; Paszko Z
Endokrynol Pol; 2006; 57(4):415-9. PubMed ID: 17006846
[TBL] [Abstract][Full Text] [Related]
48. Multiple endocrine neoplasia, the old and the new: a mini review.
Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
[TBL] [Abstract][Full Text] [Related]
49. Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.
Pelizzo MR; Torresan F; Boschin IM; Nacamulli D; Pennelli G; Barollo S; Rubello D; Mian C
Am J Clin Oncol; 2015 Oct; 38(5):508-13. PubMed ID: 24064755
[TBL] [Abstract][Full Text] [Related]
50. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
[TBL] [Abstract][Full Text] [Related]
51. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
52. Current approaches to medullary thyroid carcinoma, sporadic and familial.
Fialkowski EA; Moley JF
J Surg Oncol; 2006 Dec; 94(8):737-47. PubMed ID: 17131404
[TBL] [Abstract][Full Text] [Related]
53. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland.
Paszko Z; Sromek M; Czetwertynska M; Skasko E; Czapczak D; Wisniewska A; Prokurat A; Chrupek M; Jagielska A; Kozlowicz-Gudzinska I
Cancer Invest; 2007 Dec; 25(8):742-9. PubMed ID: 18058472
[TBL] [Abstract][Full Text] [Related]
54. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma.
Jhiang SM; Fithian L; Weghorst CM; Clark OH; Falko JM; O'Dorisio TM; Mazzaferri EL
Thyroid; 1996 Apr; 6(2):115-21. PubMed ID: 8733882
[TBL] [Abstract][Full Text] [Related]
55. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
56. Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2.
Gilchrist DM; Morrish DW; Bridge PJ; Brown JL
Clin Genet; 2004 Oct; 66(4):349-52. PubMed ID: 15355438
[TBL] [Abstract][Full Text] [Related]
57. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease.
Bütter A; Gagné J; Al-Jazaeri A; Emran MA; Deal C; St-Vil D
J Pediatr Surg; 2007 Jan; 42(1):203-6. PubMed ID: 17208566
[TBL] [Abstract][Full Text] [Related]
58. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
[TBL] [Abstract][Full Text] [Related]
59. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A.
Bae SJ; Kim DJ; Kim JY; Park SY; Choi SH; Song YD; Ki CS; Chung JH
Thyroid; 2006 Jun; 16(6):609-14. PubMed ID: 16839264
[TBL] [Abstract][Full Text] [Related]
60. Invited commentary: medullary thyroid cancer: the importance of RET testing.
Evans DB; Shapiro SE; Cote GJ
Surgery; 2007 Jan; 141(1):96-9. PubMed ID: 17188173
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
